On October 3, 2024, the ELMUMY Project participated in a collaborative and insightful joint session with two other EU-funded initiatives, MULTIR and STEPUPIORS. This joint event, under the #MissionCancer initiative, served as a vibrant platform to discuss cutting-edge advancements in cancer research, fostering synergies between our projects.
The focus of the session was to explore innovative research and share insights across multiple cancer domains:
MULTIR: Dedicated to the prediction and manipulation of immune response in melanoma, lung, and bladder cancers.
STEPUPIORS: Focuses on identifying prognostic biomarkers in rectal cancer.
ELMUMY: Aims to understand the risk factors and health determinants behind the progression of monoclonal gammopathies to multiple myeloma.
Throughout the session, partners from each project had the opportunity to present their project's objectives and challenges. The discussions that ensued were engaging and productive, allowing participants to enhance the collaborative spirit within the cancer research community.
Comments